Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Stichting VU currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This indicates that the company's patent filings are being reviewed in different specialized environments at the patent office. The busiest examiner, GUSTILO, ESTELLA M, is assigned 1 busiest examiner pending office action.
Since there are 2 pending office actions and 2 distinct examiners, each examiner is handling exactly one case. The use of 2 distinct art units suggests that the organization is navigating different sets of examination priorities or technical standards. For a practitioner, this variety means that the prosecution strategy must be adaptable to the different styles of 2 distinct examiners. The portfolio shows more structural diversity than those limited to a single art unit, even with a small number of active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779936 | METHODS AND COMPOSITIONS FOR ANALYSES OF CANCER | KAPUSHOC, STEPHEN THOMAS | 71d overdue |
| 18283547 | CD38 Chimeric Co-Stimulating Receptor and Uses Thereof | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779936 | METHODS AND COMPOSITIONS FOR ANALYSES OF CANCER | KAPUSHOC, STEPHEN THOMAS | 71d overdue |
| 18283547 | CD38 Chimeric Co-Stimulating Receptor and Uses Thereof | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283547 | CD38 Chimeric Co-Stimulating Receptor and Uses Thereof | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | — | Pending | Sep 22, 2023 |
| 17779936 | METHODS AND COMPOSITIONS FOR ANALYSES OF CANCER | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Final Rejection | 71d overdue | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStichting VU has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Estella M Gustilo has the most, with 1 of Stichting VU's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
